Taglich Brothers Initiates Coverage on Pivotal Therapeutics Inc.
Published: Feb 08, 2012
NEW YORK, NY--(Marketwire - February 08, 2012) -
Taglich Brothers, Inc.
Pivotal Therapeutics Inc.
Pivotal Therapeutics Inc. (CNSX: PVO) headquartered in Woodbridge, Ontario, Canada was established in 2010. Pivotal is a development stage specialty pharmaceutical company that is currently focused on the commercialization of Vascazen, an FDA-approved prescription Omega 3 medical food product developed to reduce risk factors that led to adverse coronary events, including sudden death. Vascazen is the first of a range of proven formulations that Pivotal envisions taking to market while avoiding the costly regulatory review (New Drug Applications and Abbreviated New Drug Applications) that prescription drugs are subject to.
Pivotal introduced Vascazen in the US in November 2011. Supported by FDA-approved material suppliers and contract manufacturers, and contract logistics service and selling organizations, the company aims to begin US distribution by late February 2012.
Clinical studies prove that Omega 3, commonly referred to as fish oil, significantly reduces cardiovascular risk factors stemming from dietary deficiencies in fish oils. Omega 3 is particularly effective when formulated, as Vascazen is, with high concentrations of eicosapentaenoic acid (EPA) and docosahexanenoic acid (DHA) in optimally balanced proportions.
The complete 17-page report is available at www.taglichbrothers.com.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.
All research issued by Taglich Brothers, Inc. is based on public information. In December 2011 the company paid an initial monetary engagement fee of US$5,250 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,750 per month for a minimum of three more months for such services.
For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.
Taglich Brothers, Inc.